MarketCapExport financials
Lantheus Holdings (LNTH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Lantheus Holdings Income Statement 2025-2011 | LNTH
Brief overview of income trends at Lantheus Holdings
The conclusions below are based on five years of reported results. The revenue attributed to Lantheus Holdings moved from $339 million to $1.5 billion between the two endpoints. The cumulative result was +354.2%, corresponding to roughly 35.3% per year. The annual growth rate indicates an exceptionally strong top-line trend.
Gross profit was 139 million dollars at the start and 942 million dollars at the end of the period (+578.8%). The cost base moved more slowly than the top line, which supported margins. The gross margin was 40.9% at the start and 61.1% at the end. The business retained more gross profit from each unit of revenue.
EBITDA changed from $20.5 million to $381 million (+1759%). EBITDA expanded faster than the top line. The EBITDA share of revenue changed from 6% to 24.7%. Higher profitability strengthens the quality of operating growth.
Comparing the endpoints shows a move from −13.5 million dollars to 234 million dollars. The company restored profitability by the end of the period.
Over the period, capitalization shifted from $1 billion to $5.1 billion (+406.6%). The valuation did not keep pace with the reported progress.
Overall conclusion
The indicators form a favorable picture of business development. The constructive conclusion rests on better sales economics, positive operating leverage and a stronger final result. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Lantheus Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.12 B | 6.47 B | 4.42 B | 4.81 B | 3.23 B | 1.01 B | 699 M | 635 M | 887 M | 282 M | 53 M | - | - | - | - |
Shares |
67.5 M | 69.2 M | 68.3 M | 68.5 M | 67.5 M | 54.1 M | 39 M | 38.2 M | 37.3 M | 32 M | 24.4 M | - | - | - | - |
Historical Prices |
75.9 | 93.4 | 64.7 | 70.3 | 47.8 | 18.7 | 15.6 | 22.9 | 15.3 | 12.8 | 2.12 | - | - | - | - |
Net Income |
234 M | 312 M | 327 M | 28.1 M | -71.3 M | -13.5 M | 31.7 M | 40.5 M | 123 M | 26.8 M | -14.7 M | -3.56 M | -61.6 M | -42 M | -137 M |
Revenue |
1.54 B | 1.53 B | 1.3 B | 935 M | 425 M | 339 M | 347 M | 343 M | 331 M | 302 M | 293 M | 302 M | 284 M | 288 M | 356 M |
Cost of Revenue |
600 M | 546 M | 587 M | 353 M | 238 M | 201 M | 173 M | 168 M | 169 M | 164 M | - | - | - | - | - |
Gross Profit |
942 M | 988 M | 710 M | 582 M | 188 M | 139 M | 175 M | 175 M | 162 M | 138 M | 136 M | 126 M | 77.4 M | 75.2 M | 95.2 M |
Operating Income |
311 M | 457 M | 365 M | 36.2 M | -60.8 M | -4.2 M | 51.7 M | 64.5 M | 51.9 M | 56.6 M | 42.5 M | 39.4 M | -18.9 M | - | - |
Interest Expense |
31.3 M | 37.2 M | 20 M | 7.18 M | 7.75 M | 9.48 M | 13.6 M | 17.4 M | 18.4 M | 26.6 M | 38.7 M | 42.3 M | 42.9 M | - | - |
EBITDA |
381 M | 522 M | 425 M | 84.1 M | -18.5 M | 20.5 M | 65 M | 78.4 M | 71.1 M | 68.5 M | 62.2 M | 57.7 M | 3.79 M | -7.96 M | 15.5 M |
Operating Expenses |
- | - | - | - | - | - | 123 M | 110 M | 110 M | 87.6 M | 93 M | 86.1 M | 98.7 M | 111 M | 112 M |
General and Administrative Expenses |
275 M | 194 M | 125 M | 134 M | 150 M | 69.3 M | 61.2 M | 50.2 M | 49.8 M | 38.8 M | 43.9 M | 37.3 M | 33 M | 32.5 M | 32.9 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Lantheus Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
65.2 M | 64.7 M | 67.2 M | 68.5 M | 68.7 M | 70.9 M | 69.5 M | 69.4 M | 68.8 M | 69.9 M | 68.4 M | 68.4 M | 67.7 M | 68.9 M | 68.8 M | 68.7 M | 68 M | 67.7 M | 67.6 M | 67.5 M | 67.1 M | 66.9 M | 66.8 M | 43.1 M | 39.4 M | 39.3 M | 39.1 M | 39 M | 38.6 M | 39.3 M | 38.3 M | 38.2 M | 37.9 M | 38.5 M | 37.4 M | 37.2 M | 36.9 M | 38.5 M | 31.2 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 18.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
75 M | 118 M | 27.8 M | 78.8 M | 72.9 M | - | 131 M | 62.1 M | 131 M | - | 132 M | 94.1 M | -2.81 M | - | 61.2 M | 43.1 M | 43 M | - | -13.4 M | -26.7 M | 9.01 M | - | -6.39 M | -7.01 M | 3.34 M | 10.4 M | 4.86 M | 6.41 M | 9.95 M | 13.3 M | 9.27 M | 9.74 M | 8.21 M | 97.1 M | 8.53 M | 13.6 M | 4.14 M | 4.87 M | 4.22 M | 7.35 M | 10.3 M | 3.92 M | 5.39 M | -24.4 M | 375 K | 227 K | -867 K | -1.64 M | -1.28 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
388 M | 377 M | 384 M | 378 M | 373 M | - | 379 M | 394 M | 370 M | - | 320 M | 322 M | 301 M | - | 239 M | 224 M | 209 M | - | 102 M | 101 M | 92.5 M | - | 88.5 M | 66 M | 90.7 M | 89.3 M | 85.8 M | 85.7 M | 86.5 M | 86.3 M | 88.9 M | 85.6 M | 82.6 M | 81.2 M | 79.9 M | 88.8 M | 81.4 M | 74.4 M | 73.1 M | 78 M | 76.5 M | 71.2 M | 74.1 M | 73.3 M | 74.8 M | 77 M | 75.7 M | 75.6 M | 73.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
146 M | 146 M | 162 M | 137 M | 135 M | - | 137 M | 138 M | 128 M | - | 120 M | 119 M | 224 M | - | 91.9 M | 85.7 M | 79.8 M | - | 59.4 M | 55 M | 51.5 M | - | 52.3 M | 40.2 M | 52.7 M | - | 44.2 M | 41.1 M | 42.4 M | - | 44 M | 41.7 M | 40.3 M | - | 41.4 M | 42.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
242 M | 231 M | 222 M | 241 M | 238 M | - | 242 M | 256 M | 242 M | - | 200 M | 203 M | 77.1 M | - | 147 M | 138 M | 129 M | - | 42.7 M | 46.1 M | 41 M | - | 36.3 M | 25.8 M | 38 M | 44.6 M | 41.6 M | 44.6 M | 44.1 M | 43.8 M | 44.9 M | 43.8 M | 42.3 M | 37.9 M | 38.5 M | 45.9 M | 39.8 M | 34.6 M | 33.7 M | 35.8 M | 33.7 M | 33.4 M | 33.7 M | 32.7 M | 35.8 M | 32.8 M | 31.6 M | 31.1 M | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
100 M | 81.3 M | 43.6 M | 88 M | 102 M | - | 134 M | 103 M | 107 M | - | 112 M | 124 M | -9.34 M | - | 85.7 M | 63.2 M | 58.9 M | - | -14.3 M | -26.8 M | 15.6 M | - | -5.25 M | -5.54 M | 7.12 M | - | 8.52 M | 14.5 M | 16.2 M | - | 16.5 M | 15.9 M | 15.1 M | - | 12.8 M | 17.9 M | 11.9 M | - | 12.6 M | 14.2 M | 17.7 M | - | 13.4 M | 5.36 M | 11.4 M | - | 9.22 M | 9.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
7.86 M | 5.71 M | 2.56 M | 6.9 M | 14.1 M | - | 9.95 M | 9.04 M | 8.79 M | - | 52.6 M | 4.48 M | 4.99 M | - | 1.63 M | 1.47 M | 1.51 M | - | 1.57 M | 1.94 M | 2.72 M | - | 2.81 M | 1.91 M | 1.95 M | - | 2.36 M | 4.54 M | 4.59 M | - | 4.45 M | 4.3 M | 4.05 M | - | 4.44 M | 4.28 M | 5.42 M | - | 6.79 M | 6.98 M | 7.02 M | - | 7.1 M | 13.9 M | -383 K | - | 441 K | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
145 M | 104 M | 58.2 M | 96 M | 116 M | - | 146 M | 113 M | 122 M | - | 124 M | 137 M | 5.27 M | - | 89.6 M | 66.5 M | 70.7 M | - | 15.8 M | -23.6 M | 23.7 M | - | 11 M | 2.22 M | 10.9 M | - | 18.4 M | 21.1 M | 19.5 M | - | 27 M | 23 M | 18.7 M | - | 27.8 M | 29.2 M | 18.1 M | - | 25.3 M | 22.6 M | 21.8 M | - | 30.1 M | 17.9 M | 19.5 M | - | 24 M | 19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.9 M | - | 20.3 M | 27.3 M | 24.4 M | - | 22.4 M | 21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
20.6 M | 57.5 M | 81.9 M | 66.5 M | 56.8 M | - | 40.5 M | 47.4 M | 47.9 M | - | 35.7 M | 26.2 M | 23.3 M | - | 23.8 M | 32.6 M | 37.6 M | - | 28.6 M | 43.2 M | 16.1 M | - | 18.2 M | 20.7 M | 16.7 M | - | 18.1 M | 13.3 M | 12.6 M | - | 13.6 M | 11.6 M | 12.5 M | - | 12.1 M | 11.2 M | 12.3 M | - | 10.1 M | 9.24 M | 9.51 M | - | 9.21 M | 15.4 M | 9.12 M | - | 11 M | 8.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Lantheus Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
$ 1.71 | -0.51 % | $ 4.98 M | USA |
 |
Myriad Genetics
MYGN
|
$ 5.57 | 0.54 % | $ 516 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.14 | 9.18 % | $ 642 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | 1.52 % | $ 133 M | USA |
 |
Agilent Technologies
A
|
$ 177.75 | 2.74 % | $ 50.5 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 344.87 | 9.31 % | $ 17.1 B | USA |
 |
Biodesix
BDSX
|
$ 23.93 | 0.25 % | $ 181 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.51 | 6.71 % | $ 142 M |  China |
 |
Bioventus
BVS
|
$ 14.24 | 2.08 % | $ 949 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
$ 70.74 | 2.23 % | $ 3.77 B | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.64 | -0.82 % | $ 851 K | USA |
 |
Danaher Corporation
DHR
|
$ 233.86 | 4.32 % | $ 167 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.13 | -0.98 % | $ 620 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
IQVIA Holdings
IQV
|
$ 276.63 | 3.28 % | $ 47.6 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 323.75 | 0.19 % | $ 26.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.71 | 1.12 % | $ 88 K | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 61.56 | 2.6 % | $ 2.88 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
$ 662.48 | 6.43 % | $ 19.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 677.94 | 2.69 % | $ 34.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 17.04 | 2.53 % | $ 2.18 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.79 | 0.6 % | $ 2.56 B | USA |
 |
National Research Corporation
NRC
|
$ 20.31 | -1.84 % | $ 455 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 11.98 | -0.42 % | $ 407 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.23 | 0.85 % | $ 24.9 B |  Niderland |
 |
Precipio
PRPO
|
$ 21.25 | -2.16 % | $ 34.1 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.37 | 3.68 % | $ 996 M | USA |
 |
Guardant Health
GH
|
$ 166.66 | 2.5 % | $ 20.9 B | USA |
 |
RadNet
RDNT
|
$ 68.41 | -1.78 % | $ 5.14 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 3.68 | -9.8 % | $ 14.7 M | Israel |
 |
DexCom
DXCM
|
$ 80.26 | -6.39 % | $ 31.3 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.97 | -2.92 % | $ 333 M | USA |
 |
Illumina
ILMN
|
$ 282.86 | 5.57 % | $ 43.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |